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Abstract
Background Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through 
bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 
15 (ISG15) LVI status. Thus, we explored the prognostic significance of ISG15 in BC.
Methods The prognostic significance of ISG15 mRNA was assessed in METABRIC (n = 1980), TCGA (n = 854) and 
Kaplan–Meier Plotter (n = 3951). ISG15 protein was evaluated using immunohistochemistry (n = 859) in early-stage inva-
sive BC patients with long-term follow-up. The associations between ISG15 expression and clinicopathological features, 
expression of immune cell markers and patient outcome data were evaluated.
Results High mRNA and protein ISG15 expression were associated with LVI, higher histological grade, larger tumour size, 
hormonal receptor negativity, HER2 positivity, p53 and Ki67. High ISG15 protein expression was associated with HER2-
enriched BC subtypes and immune markers (CD8, FOXP3 and CD68). High ISG15 mRNA and ISG15 expressions were 
associated with poor patient outcome. Cox proportional multivariate analysis revealed that the elevated ISG15 expression 
was an independent prognostic factor of shorter BC-specific survival.
Conclusion This study provides evidence for the role of ISG15 in LVI development and BC prognosis. Further functional 
studies in BC are warranted to evaluate the therapeutic potential of ISG15.
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Introduction
Although the progression of breast cancer (BC) involves 
a complicated multi-step process, migration is one of the 
principal steps that is responsible for tumour progression 
from the in situ to the invasive stage, stromal and lympho-
vascular invasion (LVI) and development of metastasis. As 
the outcome of cancer is largely determined by its ability 
to produce distance metastasis, understanding the mecha-
nisms underlying BC metastasis and investigations of LVI 
is warranted. LVI is a strong prognostic factor in BC, par-
ticularly in the early-stage disease and is associated with 
cancer-related mortality [1–4]. However, identifying the 
molecular mechanisms underlying LVI and its driver genes 
that can be targeted to prevent or reduce metastasis remains 
a challenge [1].
A previous study, reported by our team, has elucidated the 
mechanistic association between gene expression and LVI 
positivity [5]. The 99 deferentially expressed genes (DEGs) 
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that showed association with LVI exhibited 42 significantly 
upregulated genes and 57 significantly downregulated genes 
based on weighted average differences (WAD) [5, 6]. Fur-
thermore, when gene set enrichment analysis (GSEA) [7] 
was applied to the molecular panel previously identified by 
WAD approach, cell migration was the top of the main regu-
lators of the gene panel.
Interferon-stimulated gene 15 (ISG15) encodes ISG15 
(ubiquitin-like protein) which is highly expressed in almost 
all tumours and is stimulated by type I interferons. As a con-
sequence of immune cell infiltration into the tumour stroma 
and because these cells are the main source of interferon 
α and β, this may lead to increased ISG15 expression in 
tumour cells [8]. Moreover, ISG15 is detected as a conju-
gated protein that links to multiple target proteins in what 
is called ISGylation process, but it can also be found in free 
or unconjugated status. In ISGylation, the ISG15 protein 
attaches and modifies a target protein in a similar way to 
the ubiquitylation process [9]. ISGylation plays a key role 
in the inhibition of protein translation either via inhibiting 
eIF2α by ISGylation of dsRNA-dependent protein kinase 
[10] or via enhancing the cap-structure-binding activity of 
the ISGylated translational suppressor 4EHP [11]. ISG15 
has been reported to play a significant role in tumour micro-
environment via enhancing T cells, B cells and epithelial cell 
lines cytokines [12]. A previous study has suggested that the 
secretion of ISG15 has an influence on T and NK cells to 
prompt IFNγ production and may have a significant role in 
the innate immunity [13]. Moreover, the extracellular ISG15 
acts as an immune adjuvant that promotes antigen-specific 
CD8 + T cell tumour immunity [14]. In ovarian cancer, 
ISG15 can stimulate CD8 + T cell proliferation by activating 
NK cells, which enhance the cytokines production such as 
IL2 and IFNγ [15]. ISG15 is also highly correlated with the 
expression of the macrophage marker CD68 and it appears to 
mediate the cellular expression of multiple cytokines in mac-
rophage through the regulation of p38 phosphorylation [16].
High ISG15 has been shown to be accompanied by cer-
tain oncogenic proteins facilitating tumour oncogenesis 
by inhibiting cells that control apoptosis in both primary 
tumour (with high α and β interferons) and during metastasis 
(when the interferons decrease) [8]. However, its role in LVI 
and cancer metastasis remains unclear. A previous study that 
has investigated the role of ISG15 in tumour progression and 
invasion suggested that high expression of ISG15 enhances 
the cancer cell migration invasion and metastasis [9]. ISG15 
alters multiple proteins, including focal adhesion protein, 
action binding or modifying proteins to improve their func-
tion or increase their stability to facilitate the cancer cell 
migration, such as binding with Rac1 in oral squamous cell 
carcinoma [17]. The upregulation of ISG15 was identified 
as a critical gene strongly associated with BC progression 
and metastasis via modulating the cell architecture and 
enhancing the cancer cell motility [9]. Moreover, BC cell 
lines showed significantly elevated expression of ISG15 
compared with normal cell lines, and the knockdown of 
ISG15 expression was reduced ZR-75-1 cell motility in cell 
migration assay compared to the wild type [18]. However, 
the biological and prognostic value of ISG15 expression in 
BC remains to be defined.
In our previous studies aiming to identify the driver of 
LVI in BC [1, 5], ISG15 was in the differentially identified 
genes associated with LVI. This study aimed to validate the 
prognostic significance of ISG15 defined by our gene sig-
nature [5] and evaluate its association with well-established 
prognostic variables including LVI, relevant biomarkers 
related to ISG15 function/expression and patient outcome.
Materials and methods
Study cohorts
ISG15 mRNA expression was assessed using the Molecu-
lar Taxonomy of Breast Cancer International Consortium 
(METABRIC) datasets (n = 1980) [19] and The Can-
cer Genome Atlas (TCGA) (n = 854) [20]. The Illumina 
Human HT-12 v3 platforms (Illumina, Inc., San Diego, 
USA) were used in the METABRIC to analyse/evaluate 
mRNA extracted from primary tumour samples. In TCGA, 
RNASeqV2 data and clinicopathological information pro-
vided by cBioPortal website were used [21, 22]. The cut-off 
point was determined using the median for both METABRIC 
cohort (9.5) and TCGA cohort (1007) to categorise into high 
and low subgroups. For further validation of the prognostic 
significance of ISG15 in BC, an online analytical module the 
Kaplan–Meier Plotter (n = 3951) [23] was employed.
ISG15 protein expression was evaluated using a well-
characterised cohort of BC (n = 667) collected from patients 
presented to Nottingham City Hospital, NHS Trust between 
1989 and 1998 as previously described [24]. Patients were 
classified for management purposes into clinically relevant 
groups based on the Nottingham Prognostic Index (NPI) 
and Oestrogen Receptor (ER) status as previously described 
[2]. Patients were divided into two subgroups according to 
their NPI level; patients with NPI ≤ 3.4 received no adju-
vant therapy, whereas patients who had NPI > 3.4 received 
chemotherapy if ER status negative and received tamoxifen 
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as a hormonal therapy if ER status was positive. Classical 
cyclophosphamide, methotrexate and 5-flurouracil (CMF) 
were used as a therapy for patients who lacked ER expres-
sion and were eligible to receive chemotherapy. This was in 
accordance with the local BC management protocol during 
the period of the study patients’ presentation. Patients in this 
study did not receive neoadjuvant therapy or anti-human 
epidermal growth factor receptor 2 (HER2)-targeted therapy.
Data on ER, progesterone receptor (PR), Ki67 expres-
sion and HER2 status were available as previously published 
[25, 26]. ER and PR cut-off points were previously defined 
as ≥ 1% [26–28]. Ki67 cut-off was previously defined as ≥ 10 
[29]. Information on the clinical history, clinicopathological 
variables, outcome and therapy was collected from patients’ 
clinical notes. Outcome data included the time of develop-
ment of BC and BC-specific survival (BCSS) where the lat-
ter is defined as the time in months from the date of primary 
surgery to the time of the patient’s death due to BC.
For further understanding the protein interactions of high 
ISG15, available protein data from our cohort on tumour 
prognostic markers (P53 and Ki67), epidermal growth 
factor receptor (EGFR), EMT-related marker (E-cadherin 
(CDH1)), stem cell marker (CD44) and stromal T infiltra-
tive lymphocyte markers (TILs) (CD8, FOXP3 and CD68) 
were included in this study as per previous publications 
[29–35] (Supplementary Table 1).
Immunohistochemistry (IHC)
ISG15 protein expression was evaluated using immunohis-
tochemistry preceded by validation of the ISG15 antibody 
specificity using Western blot [rabbit polyclonal antibody 
(ab227541); Abcam Company, UK] cell lysates of MCF7, 
SKBR3, MB-MDA-231 and MB-MDA-468 (obtained from 
the American Type Culture Collection; Rockville, MD, 
USA). The rabbit anti-ISG15 antibody (1/800) was incu-
bated overnight at 4 °C and after being exposed to an appro-
priate secondary antibody, a single band at approximately 
42 KDa was detected using fluorescent secondary antibod-
ies at (1:15,000) (IR Dye 800CW donkey anti-rabbit and 
680RD donkey anti-mouse, LI-COR Biosciences, UK). The 
mouse anti-β-actin antibody (A5441, Sigma-Aldrich; Clone 
AC-15; Sigma, UK) at 1:5000 was used as a house-keeping 
protein and showed a band at approximately 42 KDa (Sup-
plementary Fig. 1A and B). Moreover, as recommended by 
the manufacturer, HELA cell lysate was used as the posi-
tive control and the specificity of the antibody was validated 
with a single specific band at the predicted molecular weight 
(~ 42KDa) (Supplementary Fig. 1C).
To assess the distribution of ISG15 expression within the 
BC tissue, 14 full-face sections of BC cases, representa-
tive of various molecular subtypes and tumour grade, were 
stained prior to TMA staining and evaluation. We have 
observed that ISG15 was homogenously distributed through-
out these tissue sections, which indicate suitability of TMA 
to assess expression of ISG15 in breast cancer epithelial 
tumour cells. TMA Grand Master® (3D HISTECH®, Buda-
pest, Hungary) was used to array the tumour samples into 
TMAs as previously described [36]. Heat-induced citrate 
antigen retrieval (pH 6.0) was utilised and samples were 
incubated with the ISG15 antibody (1:500) at room tempera-
ture for 1 h. Finally, ISG15 immunoreactivity was detected 
using the Novolink Max Polymer Detection kit (Leica, New-
castle, UK) and following the manufacturer’s instructions. 
Normal kidney tissue was used as a positive tissue control 
(Supplementary Fig. 1D).
Scoring
Nanozoomer scanner (Hamamatsu Photonics, Welwyn Gar-
den City, UK) was used to scan the stained sections with 
high-resolution digital images at × 20 magnification. Modi-
fied H-score was manually used to evaluate the ISG15 cyto-
plasmic immunoreactivity by calculating the staining inten-
sity and percentage of positivity. The proportion of tumour 
cells (0–100) was multiplied by the staining intensity (0–3) 
and the final scores were obtained, giving a range of 0–300 
[37]. Some TMA cores were regarded as non-informative 
if they contain less than 15% tumour cells or when they 
are folded cores. A blind double scoring was performed by 
two researchers (YK and SA) to evaluate the interobserver 
concordance. Intraclass correlation coefficient (ICC) con-
cordance showed good reliability between both observers 
(0.85) and discordant cases were rescored by both observers 
to reach a final agreement. To categorise high and low sub-
groups, the median was used to generate cut-off for ISG15 
protein (35-H-score) expression levels.
Statistical analysis
Statistical analysis was accomplished by using SPSS (IBM 
SPSS Statistics, Version 24.0). Pearson correlation test was 
used to assess the association between ISG15 mRNA expres-
sion and the expression of a set of genes correlated with epi-
thelial–mesenchymal transition (EMT) [38] and cancer cell 
migration [24] (CDH1 (E-cadherin), CDH2 (N-cadherin), 
Transforming Growth Factor Beta 1 (TGFB1), Twist Family 
BHLH Transcription Factor 2 (TWIST2), Twist Family BHLH 
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Transcription Factor 2 (TWIST1), Zinc Finger E-box Binding 
Homeobox2 (ZEB2), Zinc Finger E-box Binding Homeobox1 
(ZEB1), Snail family Transcriptional Repressor 2 (SLUG), 
SNAIL, Nuclear Factor Kappa B Subunit 1 (NFKB1), Lethal 
Giant Larvae Homolog 2 (LLGL2), Glycogen synthase Kinase 
3 Beta (GSK3B), Crumbs Cell Polarity Complex Component 
1 (CRUMBS) and Catenin Beta 1 (CTNNB1). The associa-
tion between ISG15 mRNA expression and the expression of 
Matrix Metalloproteinase (MMPs) genes in the METABRIC 
cohort was also analysed. Chi-square test was used to evaluate 
the correlation between the clinicopathological features and 
ISG15 protein expression where data are available. The prog-
nostic significance of ISG15 expression was determined via 
Kaplan–Meier survival curves using log-rank test. Multivari-
ate survival analysis was assessed by using Cox proportional 
hazard method. Both ISG15 mRNA/protein expressions were 
abnormally distributed and therefore were dichotomised by 
median cut-off value. The statistical significance of clinico-
pathological factors and survival was defined by p value < 0.05 
(two-tailed). This work was performed according to REMARK 
guidelines or tumour prognostic study [39] and approved ethi-
cally by the North West–Greater Manchester Central Research 
Ethics Committee under the title: Nottingham Health Science 
Biobank (NHSB), reference number 15/NW/0685.
Bioinformatics investigation and pathway analysis
The molecular biology of ISG15 mRNA expression was inves-
tigated at the transcriptomic level using a subset of META-
BRIC and TCGA cohorts [19]. Regardless of LVI status, the 
restriction was based on the PAM50 molecular classifica-
tion using only HER2-enriched and luminal B cases as our 
proteomic and transcriptomic revealed a strong association 
of ISG15 expression with LVI and patient outcome in these 
two subtypes. Nevertheless, the differential gene expression 
(DGE) analysis was performed using the Robina implemen-
tation of Edge-R statistical tool [40]. The dichotomisation 
of cases into high versus low groups relied on the median of 
ISG15 mRNA expression in both cohorts. Henceforth, high 
expression of ISG15 mRNA in the METABRIC cohort is dis-
played in 364/728 cases (50.0%), whereas in the TCGA cohort, 
ISG15 mRNA high expression was observed in 137/275 cases 
(49.8%). DGE was performed in two categories: (A) cases 
harbouring high ISG15 mRNA expression against cases har-
bouring low ISG15 mRNA expression within the META-
BRIC cohort and (B) cases harbouring high ISG15 expression 
against cases harbouring low ISG15 mRNA expression within 
the TCGA cohort.. Common genes that were found to drive the 
ISG15 mRNA expression in both the METABRIC and TCGA 
cohorts were identified using the Venny 2.0 online tool [41].
To explore targetable, the online public available web-
based Gene ontology enrichment analysis and visualisation 
tool (GORILLA) [42] gene set analysis tool was used to 
identify differentially regulated canonical pathways. This 
pathway analysis calculated the significantly enriched path-
ways for the genes common to ISG15 mRNA overexpression 
in both METABRIC and TCGA cohorts based on genes dif-
ferentially expressed at the p < 0.05 level and generated by 
Robina analysis, including only unbiased hits with a signifi-
cant enrichment score [42].
Results
ISG15 mRNA expression and association 
with clinicopathological parameters and outcome
In both METABRIC and TCGA cohorts, high ISG15 
mRNA expression was correlated with LVI and other 
variables of poor prognosis, including high tumour grade, 
hormone receptor negativity [ER and PR], HER2 positiv-
ity and expression of EGFR and stem cell CD44) marker 
(Table 1). High ISG15 expression was also associated with 
larger tumour size and positive nodal status in the META-
BRIC cohort (Table 1). Moreover, when we distributed 
the mRNA expression of ISG15 according to histological 
tumour subtypes, high mRNA expression of ISG15 was 
significantly associated with ductal no special type (NST) 
BC compared to lobular BC subtype in the METABRIC 
cohort (p < 0.001), but not in the TCGA cohort (p = 0.710) 
(Table 1).
High ISG15 mRNA expression was positively correlated 
with the expression of EMT-related markers LLGL2 and 
CTNNB1 (Table 2) and with multiple MMPs biomarkers 
including MMP9, MMP11, MMP13, MMP21 and MMP28 
(Table 2).
In METABRIC and KM-Plotter dataset, outcome analysis 
indicated an association between high ISG15 mRNA expres-
sion and shorter BCSS (p < 0.001, Fig. 1a and b). In TCGA, 
high ISG15 mRNA expression showed similar trend, but did 
not reach statistical significance (p = 0.335, Fig. 1c).
When we stratified the METABRIC mRNA cohorts based 
on LVI and HER2 status, high ISG15 mRNA expression 
was associated with poor survival in LVI-positive sub-
group (p < 0.001, Fig. 1d) and in the HER2-positive sub-
group (p < 0.001; Fig. 1e). A trend towards similar asso-
ciations with poor survival was observed in the TCGA 
cohort for both LVI-positive and HER2-positve cases 
that did not reach statistical significant (p = 0.415, Fig. 1f 
and p = 0.174, Fig. 1g, respectively). Nonetheless, when 
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METABRIC (n = 1980) and 
TCGA (n = 895) datasets
Significant correlations are in bold
Parameters METABRIC cohort TCGA cohort
Low ISG15 High ISG15 p value Low ISG15 High ISG15 p value
N (%) N (%) N (%) N (%)
Tumour size
 ≤ 2.0 cm 454 (53) 405 (47) 0.003 131 (31) 108 (45) 0.087
 > 2.0 cm 526 (48) 575 (52) 297 (48) 318 (52)
Nodal status
 Negative 543 (53) 492 (47) 0.018 216 (51) 207 (49) 0.606
 Positive 492 (52) 496 (53) 210 (49) 216 (51)
Histological grade
 Grade 1 and 2 551 (59) 390 (41)  < 0.001 268 (58) 196 (42)  < 0.001
 Grade 3 389 (41) 562 (59) 141 (55) 211 (60)
Tumour histological subtypes
 Ductal NST 705 (46) 839 (54)  < 0.001 212 (48) 227 (52) 0.710
 Lobular 105 (710 42 (29) 69 (52) 63 (48)
 Medullary-like 20 (62) 12 (38) 15 (58) 11 (42)
 Special type 139 (69) 64 (31) 14 (52) 13 (48)
Lymphovascular invasion
 Negative 482(52) 448(48) 0.037 258 (46) 301 (54) 0.002
 Positive 295(47) 340(53) 169 (57) 126 (43)
Oestrogen receptor
 Negative 207 (44) 267 (56) 0.002 74 (40) 111 (60) 0.003
 Positive 783 (52) 723 (48) 335 (52) 304 (48)
Progesterone receptor
 Negative 416 (44) 524 (56)  < 0.001 150 (44) 152 (56) 0.029
 Positive 574 (55) 466 (45) 285 (52) 261 (48)
Human epidermal growth factor receptor 2
 Negative 883 (51) 850 (49) 0.025 298 (53) 296 (47) 0.013
 Positive 107 (43) 140 (57) 54 (41) 79 (59)
Epithelial growth factor receptor
 Negative 537 (54) 453 (46)  < 0.001 245 (57) 182(43)  < 0.001
 Positive 453 (46) 537 (54) 183 (43) 244 (57)
CD44
 Negative 542 (55) 448 (45)  < 0.001 249 (58) 117 (42)  < 0.001
 Positive 448 (45) 542 (55) 178 (42) 249 (58)
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performing survival analysis to test the value of ISG15 
mRNA expression on both the METABRIC and TCGA 
cohorts after restriction to the LVI-negative and HER2-
negative cases, our data showed no statistical association 
with patients outcome (p > 0.05) (Supplementary Fig. 2A, 
B, C and D, respectively).
ISG15 pathway analysis
Our DGE investigation identified a total of 807 differentially 
regulated genes associated with ISG15 mRNA expression in 
both cohorts. Within the METABRIC cohort, high ISG15 
mRNA expression displayed 1401 overexpressed and 1874 
downregulated genes. Likewise, in the TCGA cohort, high 
ISG15 mRNA expression displayed 2389 overexpressed and 
1872 downregulated genes. Remarkably, the overlapping of 
high and low DEGs of both cohorts between cases harbour-
ing high ISG15 mRNA expression against cases harbouring 
low ISG15 mRNA expression in both cohorts included 490 
common overexpressed and 317 common downregulated 
genes associated with ISG15 mRNA expression (Fig. 2a). 
Analysis of the 490 commonly overexpressed genes identi-
fied over-represented gene ontology (GO) terms associated 
with epithelial cell migration which highlights the role of 
ISG15 in tumour oncogenesis. The common low-expressed 
genes showed no GO terms with enrichment p value above 
the specified p value threshold (p = 0.001) (Fig. 2b) (Sup-
plementary Table 2).
ISG15 protein expression
The expression of ISG15 showed significant correlation 
between transcriptomic level and protein level using Pear-
son correlation test (p = 0.042). Within the 14 BC full-face 
sections, normal breast terminal duct lobular unit (TDLU) 
showed faint to weak expression of ISG15 compared to 
higher expression of ISG15 in invasive breast tissue (Sup-
plementary Fig. 1E and F, respectively). For dichotomisation 
into negative/low and high expression, the median H-score 
35 was used. Out of 674 informative TMA cores, negative/
low expression was observed in 275 cases (Supplementary 
Fig. 1G), while 399 cases (59%) showed high ISG15 expres-
sion (Supplementary Fig. 1H).
High expression of ISG15 protein was significantly asso-
ciated with LVI positivity and other features of poor progno-
sis including younger age at diagnosis, larger tumour size, 
high grade, poor NPI, lack of expression of ER and PR and 
HER2 positivity (Table 3). Moreover, when we distributed 
the protein expression of ISG15 according to BC tumour 
IHC subtypes, high protein expression of ISG15 showed a 
significant association with ductal no special type (NST) BC 
tumour compared to lobular BC type (p = 0.003) (Table 3). 
Furthermore, when we compared ISG15 protein expression 
with BC progression-associated markers, high ISG15 pro-
tein expression was significantly associated with the high 
expression of P53, Ki67, EGFR and CD44, and high stromal 
immune markers of CD8, FOXP3 and CD68. However, it 
Table 2  Correlation of high ISG15 mRNA expression with mRNA 
expression of EMT- and MMPs-related genes
Significant correlations are in bold
Gene names METABRIC cohort TCGA cohort
Correlation 
value




CDH1  − 0.034 0.127 0.032 0.353
CDH2 0.010 0.650 0.004 0.912
TGFB1 0.041 0.068 0.065 0.056
TWIST2  − 0.152  < 0.001 0.033 0.329
TWIST1  − 0.042 0.061 0.014 0.688
ZEB2  − 0.103  < 0.001  − 0.038 0.268
ZEB1  − 0.168  < 0.001  − 0.044 0.197
SLUG  − 0.142  < 0.001  − 0.002 0.956
SNAIL 0.057 0.012 0.011 0.738
NFKB1  − 0.107  < 0.001  − 0.005 0.889
LLGL2 0.102  < 0.001 0.068 0.047
GSK3B 0.211  < 0.001  − 0.042 0.216
CRUMBS  − 0.018 0.422  − 0.012 0.727
CTNNB1  − 0.165  < 0.001  − 0.010 0.040
MMPs-related genes
MMP9 0.218  < 0.001 0.030 0.035
MMP11 0.152  < 0.001 0.116 0.001
MMP13 0.055 0.004 0.023 0.023
MMP14 0.065 0.015 0.008 0.854
MMP15 0.096  < 0.001 0.044 0.198
MMP20 0.050 0.025 0.016 0.639
MMP21 0.045 0.047 0.097 0.005
MMP25 0.076 0.003 0.011 0.746
MMP28 0.248  < 0.001 0.099 0.004
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Fig. 1  Patients’ outcomes of Breast cancer survival on Transcrip-
tomic level. a Cumulative survival of BC patients stratified by 
ISG15 mRNA expression in the METABRIC cohort. b Cumulative 
survival of BC patients stratified by ISG15 mRNA expression in 
the KM-Plotter cohort. c Cumulative survival of BC patients ISG15 
mRNA expression in the TCGA cohort. d Cumulative survival of BC 
patients stratified by ISG15 mRNA expression in the METABRIC-
restricted LVI-positive cohort. e Cumulative survival of BC patients 
stratified by ISG15 mRNA expression in the METABRIC-restricted 
HER2-positive cohort. f Cumulative survival of BC patients strati-
fied by ISG15 mRNA expression in the TCGA-restricted LVI-posi-
tive cohort. g Cumulative survival of BC patients stratified by ISG15 
mRNA expression in the TCGA-restricted HER2-positive cohort
Fig. 2  Differential gene expression and pathway analysis. a Over-
lapping differentially expressed genes associated with high ISG15 
mRNA expression. Cases depicting (I) overexpressed differen-
tially expressed genes associated with high ISG15 mRNA on both 
METABRIC and TCGA restricted on Luminal B and HER2-positive 
cohorts. (II) Overlapping downregulated differentially expressed 
genes associated with High ISG15 mRNA on both METABRIC and 
TCGA restricted on Luminal B and HER2-positive cohorts. DGE: 
differentially expressed gene, (↓): downregulated genes,  (↑) over-
expressed genes. b The enriched biological process generated by 
the common 490 overexpressed genes based on high ISG15 mRNA 
expression on both METABRIC and TCGA restricted on Luminal B 
and HER2-positive cohorts
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showed negative association with tumour E-cadherin expres-
sion (Table 3).
Outcome analysis showed an inverse association between 
ISG15 protein expression and survival; high expression was 
associated with shorter BCSS (p = 0.008; Fig. 3a). Multi-
variate analysis demonstrated that high protein expression of 
ISG15 was associated with shorter BCSS [p = 0.026, Hazard 
ratio, 1.3, 95% CI 1.0–1.6], independent of other established 
prognostic factors including LVI, tumour size, histological 
grade, ER and HER2 status (Table 4).
When we stratified the Nottingham BC IHC cohort based 
on the LVI and HER2 status, high protein expression of 
ISG15 was associated with poor BCSS in the LVI-positive 
survival cases (p = 0.005, Fig. 3b), and in the HER2-positive 
survival cases (p = 0.046; Fig. 3c) subgroups, similar of poor 
survival trend were observed for LVI-negative survival cases 
and HER2-negative survival cases, but it did not reach sta-
tistical significant (p > 0.05, Supplementary Fig. 2E and F, 
respectively).
Table 3  Statistical association between ISG15 protein expression and 
clinicopathological characteristics of the studies cohort
Parameters ISG15 protein expression
Low High p value
N (%) N (%)
Tumour size
 ≤ 2.0 cm 144 (45) 178 (55) 0.044
 > 2.0 cm 127 (37) 216 (63)
Nodal status
 Negative 393 (52) 369 (48) 0.192
 Positive 165 (43) 219 (57)
Histological grade
 1 43 (51) 42 (49) 0.002
 2 104 (47) 117 (53)
 3 128 (35) 238 (65)
Tumour histological subtypes
 Ductal (NST) 216 (39) 336 (71) 0.003
 Lobular 43 (61) 28 (39)
 Medullary-like 11 (79) 3 (21)
 Special type 10 (37) 17 (63)
Lymphovascular invasion
 Negative 164 (44) 210 (56)  < 0.001
 Positive 62 (30) 144 (70)
Nottingham prognostic index
 Good prognostic group 91 (51) 88 (49) 0.005
 Moderate prognostic group 134 (38) 220 (62)
 Poor prognostic group 46 (35) 86 (65)
Age
 ≤ 50 92 (36) 163 (64) 0.034
 > 50 179 (44) 232 (56)
Oestrogen receptor
 Negative 49 (30) 133 (73)  < 0.001
 Positive 222 (46) 263 (54)
Progesterone receptor
 Negative 97 (34) 186 (66) 0.008
 Positive 165 (45) 205 (55)
Human epidermal growth factor receptor 2
 Negative 243 (44) 313 (56)
 < 0.001
 Positive 19 (21) 73 (79)
P53
 Negative 201 (45) 250 (55) 0.001
 Positive 58 (29) 141 (71)
Ki67
 Negative 95(46) 111 (54) 0.008
 Positive 120 (35) 226 (65)
E-Cadherin
 Negative 109 (36) 268 (64) 0.005
 Positive 109 (48) 120 (52)
Significant correlations are in bold
Table 3  (continued)
Parameters ISG15 protein expression
Low High p value
N (%) N (%)
N-Cadherin
 Negative 52 (38) 84 (62) 0.904
 Positive 151 (39) 238 (61)
Basal-phenotype
 Negative 361 (79) 96 (21) 0.010
 Positive 246 (71) 102 (29)
Epithelial growth factor receptor
 Negative 222 (43) 298 (57) 0.03
 Positive 43 (32) 90 (68)
CD8
 Negative 116 (44) 147 (56) 0.013
 Positive 84 (33) 167 (67)
CD44
 Negative 76 (43) 100 (57) 0.005
 Positive 44 (28) 72 (72)
FOXP3
 Negative 86 (47) 99 (53) 0.019
 Positive 125 (36) 222 (64)
CD68
 Negative 85 (47) 96 (53) 0.008
 Positive 114 (35) 212 (65)
IHC subtypes
 Luminal A 100(45) 124 (55)  < 0.001
 Luminal B 50 (33) 100 (67)
 Her2 enriched 26 (20) 103 (80)
 TNBC 19 (21) 73 (79)
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Discussion
The differences in the morphological and molecular features 
of BC that determine behaviour, outcome and response to 
therapy are key characteristics that pose challenges in the 
management of BC patients. One of these challenges is the 
role of LVI in BC and understanding the underlying molecu-
lar mechanisms and drivers of LVI as potential therapeutic 
targets [1]. LVI is an essential process in the metastatic cas-
cade that needs further studies. ISG15 expression is upregu-
lated in various cancers, including breast [43], hepatocel-
lular [44], lung [45], prostate [46] and bladder [47] cancers. 
However, the association between ISG15 and BC progres-
sion, particularly its role in LVI, yet remains to be defined. 
Our study indicates a significant correlation between high 
ISG15 levels and not only LVI but also with other features of 
aggressive tumour behaviour including high tumour grade, 
large tumour size, hormone receptor negativity and overex-
pression of HER2, the immune cell markers, MMPs and the 
BC stem cell markers in addition to poor patient outcome. 
The association between high expression of ISG15 and nodal 
status in the METABRIC cohort also supports its ability 
to contribute in BC invasion and metastasis. These results 
are in accordance with several previous studies, which dem-
onstrated that ISG15 is significantly associated with can-
cer progression [17, 43–46]. Although in our study some 
variation in the association between ISG15 expression and 
clinicopathological variables such as nodal status, this can 
be attributed to the difference in the nature of cohort, con-
voluted post-transcriptional mechanisms or perhaps due to 
the substantial differences in in vivo half-lives of proteins 
[48, 49].
As observed in our study, elevated ISG15 expression is 
an independent factor of HER2 expression indicating that 
targeting ISG15 may be an attractive treatment option for 
HER2-positive and/or hormone receptor-negative tumour 
which is accompanied with severe type of BC that has no 
target therapy yet as they mainly showed resistance to hor-
monal pathway drugs [50, 51]. In mouse BC models, the 
presence of ISG15 showed a significant impact in thera-
peutic experiments via controlling CD8 expression in both 
primary and metastatic burden [44]. In the current study, 
there is a high immune response illustrated by high expres-
sion of CD8, FOXP3 and CD68, which play an important 
role in tumour microenvironment and immune response, to 
ISG15 protein expression which may also support the role 
Fig. 3  Patients’ outcomes of Breast cancer survival on Proteomic 
level. a Cumulative survival of BC patients stratified by ISG15 pro-
tein expression in the Nottingham cohort. b Cumulative survival of 
BC patients stratified by ISG15 protein expression in the Nottingham 
LVI-positive cohort. c Cumulative survival of BC patients stratified 
by ISG15 protein expression in the Nottingham HER2-positive cohort
Table 4  Multivariate Cox proportional hazard regression analysis for 
predictors of BCSS in the Nottingham BC cohort
Significant correlations are in bold
Factors BCSS
Hazard ratio 95% CI p value
ISG15 expression 1.27 1.03–1.56 0.026
Tumour size 1.70 1.37–2.12  < 0.001
Tumour grade 1.25 1.00–1.57 0.066
Lymphovascular invasion 1.85 1.50–2.23  < 0.001
ER status 0.675 0.53–0.861 0.002
HER2 status 1.73 1.33–2.25  < 0.001
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of ISG15 in controlling tumour microenvironment in BC. 
It is well known that the tumour microenvironment has an 
essential role in stromal infiltration, invasion and develop-
ment of LVI [52]. Additionally, ISG15 mRNA association 
with MMPs indicates the role in tumour progression as 
they have the ability to reorganise the extracellular matrix 
and prepare the microenvironment to produce cytokines 
that enhance cancer cell migration and proliferation [53]. 
Our data are in accordance with the previous studies for 
ISG15 in BC which indicated that ISG15 is significantly 
associated with cancer development and metastasis [8, 54].
When investigating the correlation between ISG15 mRNA 
expression and well-established EMT transcription factors, 
the results revealed a negative correlation with CTNNB, 
CDH1; however, a positive association was shown with 
LLGL2. These findings indicate that high ISG15, at both 
transcriptomic and proteomic levels, involves in promot-
ing tumour cell migration and enhancing the LVI process. 
This may occur by activating the ISGlyation that inhibits 
cancer cell-stabilising proteins through F-actin activation, 
which might also correlate with inducing proliferative pro-
teins such as P53, as our data allude [45, 55]. Furthermore, 
during metastasis, high levels of ISG15 might enhance a 
cooperative signalling by employing fibronectin-binding 
integrins such as αVβ3 and/or α5β1 to maintain high ISG15 
levels. These integrins might trigger GTPases is resulting in 
activation or polymerisation of F-actin networks and stress 
fibres, which are necessary to stimulate the cell migration 
elements such as membrane protrusions, cell contractility 
and adhesion enforcement [8]. CTNNB1 plays an important 
role in tumour cells adhesion and maintains them together 
via controlling the cell growth and adhesion between cells 
[56]. Prompting of LLGL2 plays a key role in EMT activa-
tion and was positively associated with high ISG15 mRNA 
expression. In addition, we have previously reported that 
downregulation of E-cadherin (CDH1), which was nega-
tively correlated with high protein expression of ISG15, has 
an important role in EMT activation, migration and invasion 
in BC by regulating Wnt and PI3K signalling [38]. Moreo-
ver, elevated levels of N-cadherin (CDH2), which increases 
the production of MMP9 to initiate the ideal environment for 
migratory tumour cells by rupturing the basement membrane 
in the tumour primary site, would eventually promote the 
migration process [57]. However, the last scenario might not 
necessarily be speculated in our study because no significant 
association was detected between ISG15 levels and CDH2. 
This study presented that high ISG15 at the transcriptomic 
(METABRIC cohort) and proteomic level was associated 
with EGFR, which can control EMT, migration and invasion 
[58]. Collectively speaking, the increased levels of LLGL2, 
EGFR and decreased level in CDH1, recorded in the current 
study, promote EMT and cancer cell migration in BC [9]. 
Hence, the association between ISG15 and loss of CDH1 
may result in a reciprocal inhibitory mechanism promoting 
cell migration and invasion, which may imply an indirect 
role of ISG15 in LVI.
In the whole BC cohort, high expression of ISG15 pro-
tein was an independent prognostic marker for worse BCSS. 
Among defined BC molecular subgroups, high ISG15 pro-
tein expression was observed to have the lowest survival 
rate in HER2-enriched BC. HER2 BC type was considered 
as a model in this study because it is an aggressive can-
cer that strongly associated with cancer cell migration and 
metastasis. One of the LVI prerequisites is the presence of 
specialised protrusions namely filopodia or lamellipodia to 
degrade the basement membrane through polymerisation of 
F-actin chain [59]. Therefore, targeting candidate biomark-
ers that modulate F-actin in cancer cells may help tailoring 
the treatment strategy [60–62]. It was reported that ISG15 
pathway induces BC cell conformational change leading 
to increase the tumour cell motility and metastatic ability 
through F-actin and microtubule filament modulation [9]. 
In this study, the data of DEGs and pathway analysis have 
supported the proposed role of high ISG15 association with 
epithelial cell migration particularly for Her2 and luminal B 
subtypes. This could explain the reflection of poor prognosis 
and tumour development when ISG15 is highly expressed. 
Therefore, targeting ISG15 pathway may potentially help to 
find new avenues that can be useful to precisely inhibit the 
tumour progression using personalised medicines. There-
fore, further gene ontology analyses to other IHC subtypes 
are recommended to better understand the ISG15 role in all 
BC subtypes.
The crosstalk between tumour cells and tumour microen-
vironment is well known as a complex process. Several of 
non-tumour cell factors contribute to this process and may 
play a critical role by inducing tumour aggressiveness and 
tumour cells’ migration ability into the lymphatic vessels 
and cause LVI. Therefore, further mechanistic studies are 
warranted to understand the underlying mechanisms of LVI. 
Furthermore, ISG15 protein might be expressed in other 
cells; however, this is beyond the scope of this study which 
focuses mainly on the expression in tumour epithelial cells. 
Likewise, appropriate assessment for other type of cells in 
TMA is challenging as our TMAs were constructed primar-
ily to incorporate tumour epithelial cells so the microenvi-
ronment may not be wholly representative.
In conclusion, our findings provide evidence that 
increased ISG15 at the transcriptomic and proteomic levels 
is strongly associated with LVI positivity and poor patient 
outcome in BC. Further functional in vivo and in vitro stud-
ies are warranted to identify its underlying mechanistic role 
and its therapeutic potential.
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